What is the utility of screening human embryos for polygenic traits?

Shai Carmi

Public Health

The Hebrew University of Jerusalem

scarmilab.org @ShaiCarmi

HUJI

December 2019

בית הספר לבריאות הציבור ורפואה קהילתית של האוניברסיטה העברית והדסה ע״ש בראון Braun School of Public Health and Community Medicine Hebrew University-Hadassah






האוניברסיטה העברית בירושלים




Genetic screening of embryos

- Why?
 - Mendelian disease mutations
 - Recurrent pregnancy loss
- How?
 - $_{\circ}~$ Grow IVF embryos for 3-5 days
 - $_{\circ}~$ Amplify DNA from a single cell
- What?
 - Traditionally: single mutations, aneuploidy
 - Now: whole-genome haplotypes, CNVs
 - Universal, fast, accurate, low cost






How could it be possible?



- Embryos are a mosaic of the parents
- Only need to infer crossover locations
- (Up to *de-novo* mutations)



In parallel, progress in complex trait genetics



Visscher et al., 10 Years of GWAS Discovery: Biology, Function, and Translation, AJHG, 2017

Discovery -> prediction

- Summary statistics are publicly/freely available
- Effect size:
- Quantitative traits: increase in trait with each allele (regression slope)
- Disease (binary) traits: log odds-ratio

Trait		•	•	β Allele count
()	1	2	\rightarrow

SNP	Chr	Position	Effect allele	P-value	Effect size \hat{eta}
rs1234	1	134346223	А	$2 \cdot 10^{-5}$	0.001
rs2345	3	124572521	G	$4 \cdot 10^{-3}$	-0.0006
rs3456	6	73422152	А	$2 \cdot 10^{-8}$	0.02
rs4567	14	66452342	С	$7\cdot 10^{-4}$	-0.003

Polygenic scores (PS)

• Using summary statistics, we can predict the trait of a new individual

•
$$PS = \sum_{i=1}^{M} \hat{\beta}_i g_i$$

- *M*: number of SNPs
- g_i : number of effect alleles at SNP i (0,1,2)
- $\hat{\beta}_i$: estimated effect size at SNP *i*
- Statistical methods refine the set of SNPs and the weights

Performance of polygenic scores

- h^2 : proportion of variance explained by genetics (heritability)
- h_{snp}^2 : proportion of variance explained by chip SNPs (SNP heritability)
- r_{ps}^2 : proportion of variance explained by score

 $r_{ps}^2 < h_{snp}^2 < h^2 < 1$

Trait	h^2	h_{snp}^2	r_{ps}^2	References (PMID)
Height	70-80%	46%	25%	19818695,30124842
BMI	40-70%	25%	10%	22645519, 30124842
Educational attainment	63%	22%	12%	25985137, 23722424, 30038396
Cognitive function	50%	20%	5%	25985137, 29942086
LDL cholesterol	40-50%	13%	3.1-4.7%	17903299, 23766260, 30127800
Blood pressure	47%	14%	4%	25985137, 30224653

Implications

- Screening embryos for complex traits now feasible
- At least one company is already offering the test



Screening embryos for complex traits now feasible

- From GP website:
 - Type 1 and Type 2 Diabetes
 - o Coronary Artery Disease, Heart Attack Risk, Hypercholesterolemia, Hypertension
 - Breast Cancer, Testicular Cancer, Prostate Cancer, Malignant Melanoma, Basal Cell
 <u>Carcinoma</u>
 - Intellectual Disability
 - Idiopathic Short Stature

European Journal of Medical Genetics

Validation of concurrent preimplantation genetic testing for polygenic and monogenic disorders, structural rearrangements, and whole and segmental chromosome aneuploidy with a single universal platform

Nathan R. Treff^{a,*}, Raymond Zimmerman^a, Elan Bechor^a, Jeff Hsu^a, Bhavini Rana^a, Jens Jensen^a, Jeremy Li^a, Artem Samoilenko^a, William Mowrey^a, James Van Alstine^a, Mark Leondires^b, Kathy Miller^b, Erica Paganetti^b, Louis Lello^c, Steven Avery^c, Stephen Hsu^c, Laurent C.A. Melchior Tellier^a



December 2019

Utility and First Clinical Application of Screening Embryos for Polygenic Disease Risk Reduction

Nathan R. Treff^{1,2*}, Jennifer Eccles^{1,2}, Lou Lello^{1,3}, Elan Bechor¹, Jeffrey Hsu¹, Kathryn Plunkett^{1,2}, Raymond Zimmerman^{1,2}, Bhavini Rana^{1,2}, Artem Samoilenko¹, Steven Hsu³ and Laurent C. A. M. Tellier^{1,2,3}

¹ Genomic Prediction Inc., North Brunswick, NJ, United States, ² Genomic Prediction Clinical Laboratory, North Brunswick, NJ, United States, ³ Department of Physics and Astronomy, Michigan State University, East Lansing, MI, United States

Obviously, ethical concerns

Biotechnology / DNA Testing

Eugenics 2.0: We're at the Dawn of Choosing Embryos by Health, Height, and More

Will you be among the first to pick your kids' IQ? As machine learning unlocks predictions from DNA databases, scientists say parents could have choices never before possible. MIT Technology Review November 2017 Antonio Regalado

Baby steps

A slippery slope towards designer babies? The Economist, November 2018

A new genetic-screening technique lets parents choose embryos most likely to grow into healthy adults

New Scientist, November 2018

Exclusive: A new test can predict IVF embryos' risk of having a low IQ

A new genetic test that enables people having IVF to screen out embryos likely to have a low IQ or high disease risk could soon become available in the US

The Times, November 2018 New test can predict intelligence in embryos

Obviously, ethical concerns

Embryo editing for higher IQ is afantasy. Embryo profiling for it isalmost hereSTAT, February 2019

By ERIK PARENS, PAUL APPELBAUM, and WENDY CHUNG / FEBRUARY 12, 2019

Opinion | THE PRIVACY PROJECT NY Times, April 2019 Making Babies in the Year 2045

Huge pools of health data collected over the past generation allow you to pick many of your child's genetic traits. Are you comfortable with that?

IVF couples could be able to choose the 'smartest' embryo The Guardian, May 2019


US scientist says it will be possible to rank embryos by 'potential IQ' within 10 years

BUT...

Bioethics ISSN 0269-9702 Volume 15 Number 5/6 2001

PROCREATIVE BENEFICENCE: WHY WE SHOULD SELECT THE BEST CHILDREN

JULIAN SAVULESCU




Does it work? What are the expected outcomes?

So far: economic analysis, no empirical data (Shulman and Bostrom, 2014; gwern blog)

Our approach:

- 1. Simulations based on real data
- 2. Quantitative genetic model
- 3. Large nuclear families



Gain = (prediction of top-scoring embryo) – (average prediction)

Traits/cohorts

• Height

Gil Atzmon, Nir Barzilai Einstein College of Medicine

- 102 couples, 700k SNPs
- Ashkenazi Jews, a longevity study (Sathyan et al., 2018)
- Cognitive ability (IQ)
- 919 young males, 480k SNPs
- Greek schizophrenia study (Stefanis et al., 2004)

Nikos Stefanis, Alex Hatzimanolis, Nikolaos Smyrnis, Dimitrios Avramopoulos, University of Athens


Polygenic scores

• Height

- Yengo et al., 2018
- 700k individuals


• IQ

- Savage et al., 2018
- 270k individuals
- Cross-validation for tuning parameters




Simulating embryos

- To simulate a gamete:
 - Poisson number of crossovers, random placement
 - Independent random segregation
- Gametes paired to form diploids
- Polygenic scores computed and phenotypes predicted




Experiments (n = 10 embryos)

- Gain in height: 2-4 cm
- Real/random families behave similarly
- Gain in IQ: 2-4 points



- n = 50: gain is ≈ 4.5 cm/IQ points
- n = 5: gain is ≈ 2.5 cm/IQ points



Questions

- Are these results expected?
- What happens for even more embryos?
- What happens if we have better predictors?
- We need a quantitative genetic model

•
$$PS_1, PS_2, \dots, PS_n \sim MVN(\mathbf{0}_n, \mathbf{\Sigma})$$

•
$$\Sigma = \sigma_z^2 r_{ps}^2 \begin{bmatrix} 1 & \cdots & 1/2 \\ \vdots & \ddots & \vdots \\ 1/2 & \cdots & 1 \end{bmatrix}$$

 σ_z^2 : variance of trait r_{ps}^2 : proportion of variance explained by PS

For siblings:
$$Cov(PS_i, PS_j) = \frac{1}{2}Var(PS_i)$$

• The gain: (PS of best embryo) minus (average PS for the family)

•
$$G = \max(PS_1, PS_2, ..., PS_n) - \frac{1}{n}(PS_1 + PS_2 + \dots + PS_n)$$

• $E(G) = E(\max(PS_1, PS_2, \dots, PS_n))$

Decomposing the polygenic scores

•
$$PS \sim MVN(\mathbf{0}_n, \Sigma) = Y + Z$$

•
$$\Sigma = \sigma_z^2 r_{ps}^2 \begin{bmatrix} 1 & \cdots & 1/2 \\ \vdots & \ddots & \vdots \\ 1/2 & \cdots & 1 \end{bmatrix} = \frac{1}{2} \sigma_z^2 r_{ps}^2 \begin{bmatrix} 1 & \cdots & 0 \\ \vdots & \ddots & \vdots \\ 0 & \cdots & 1 \end{bmatrix} + \frac{1}{2} \sigma_z^2 r_{ps}^2 \begin{bmatrix} 1 & \cdots & 1 \\ \vdots & \ddots & \vdots \\ 1 & \cdots & 1 \end{bmatrix}$$

Independent normals
Lindependent normals
Do not affect the max


The mean gain

- $E(G) = E(\max(Y_1, Y_2, ..., Y_n))$
- $Y_i \sim N\left(0, \frac{1}{2}\sigma_z^2 r_{ps}^2\right)$ are independent
- Using extreme value theory:


•
$$E(G) = \frac{\sigma_z r_{ps}}{\sqrt{2}} \left[\Phi^{-1} \left(1 - \frac{1}{n} \right) + \frac{\gamma}{n\phi \left(\Phi^{-1} \left(1 - \frac{1}{n} \right) \right)} \right]$$

Φ⁻¹: inverse normal CDF
 φ: normal PDF
 γ: Euler-Mascheroni constant

Confirming the theory




A useful approximation



The effect of the predictor

•
$$E(G) \propto \mathbf{r}_{ps} = \sqrt{\mathbf{r}_{ps}^2}$$


Can estimate the gain for future predictors!



Larger GWASs?

• $r_{ps}^2 = \frac{h_{snp}^2}{1 + \frac{M}{Nh_{snp}^2}}$


- *M*: Effective #markers
- N: GWAS sample size
- h_{snp}^2 : chip-based heritability
- Wray et al., 2019
- Pasaniuc and Price, 2017



10 embryos

The actual gain is uncertain


- 1. Embryos are random
- 2. Non-score genetic factors
- 3. Non-genetic factors




$$n = 10, h^2 = 0.5, r_{ps}^2 = 4.3\%$$

But what about an actual experiment?...


- Ethical issues + too long
- But we can consider large nuclear families
- 28 Ultra-orthodox Jewish families (Israel/US)
- 9.6 adult children per family (range: 3-20)
- Genotype + height available!
- Danny Zeevi, Leonid Kruglyak, UCLA



An "experiment"



- Prediction accuracy lower within families and across populations, assortative mating
- Advanced maternal age: less viable embryos
- Selection for multiple traits \circ Gain decreases by \sqrt{T} -fold
- Risk of unknown health issues





- Current gain: ≈2-3 cm/IQ points
- Improved predictors will increase the gain substantially ($\propto r_{ps}$, but only up to the heritability)

Theory

- More embryos will not ($\propto \sqrt{\log n}$)
- Actual gain uncertain and practically limited

Cell

Screening Human Embryos for Polygenic Traits Has Limited Utility

Ehud Karavani,^{1,18} Or Zuk,^{2,18} Danny Zeevi,³ Nir Barzilai,^{4,5} Nikos C. Stefanis,^{6,7,8} Alex Hatzimanolis,^{6,8} Nikolaos Smyrnis,^{6,7} Dimitrios Avramopoulos,^{9,10} Leonid Kruglyak,^{3,11,12} Gil Atzmon,^{4,5,13} Max Lam,^{14,15,16} Todd Lencz,^{14,15,17,*} and Shai Carmi^{1,19,*}

Acknowledgements:

Ehud Karavani, HUJI Or Zuk, HUJI Danny Zeevi, UCLA Todd Lencz, Northwell

Abisch-Frenkel Foundation